Viking Therapeutics (VKTX) Set to Announce Earnings on Wednesday

Viking Therapeutics (NASDAQ:VKTX) is scheduled to be announcing its earnings results after the market closes on Wednesday, October 23rd. Analysts expect the company to announce earnings of ($0.24) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings results on Wednesday, July 24th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.06. During the same period in the previous year, the business posted ($0.19) earnings per share. On average, analysts expect Viking Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Viking Therapeutics Stock Down 2.2 %

VKTX opened at $64.34 on Tuesday. The firm has a 50-day simple moving average of $62.64 and a two-hundred day simple moving average of $61.84. Viking Therapeutics has a 52 week low of $8.28 and a 52 week high of $99.41. The company has a market capitalization of $7.09 billion, a PE ratio of -69.18 and a beta of 1.00.

Wall Street Analysts Forecast Growth

Several research firms have commented on VKTX. HC Wainwright reissued a “buy” rating and set a $90.00 price objective on shares of Viking Therapeutics in a report on Wednesday, October 9th. StockNews.com raised shares of Viking Therapeutics to a “sell” rating in a report on Tuesday, October 15th. JPMorgan Chase & Co. started coverage on shares of Viking Therapeutics in a report on Wednesday, September 11th. They set an “overweight” rating and a $80.00 price objective for the company. Raymond James increased their price target on shares of Viking Therapeutics from $116.00 to $118.00 and gave the company a “strong-buy” rating in a report on Thursday, July 25th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $105.00 price target on shares of Viking Therapeutics in a report on Thursday, September 12th. One analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $108.60.

Insiders Place Their Bets

In other Viking Therapeutics news, CEO Brian Lian sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $69.90, for a total value of $69,900.00. Following the completion of the sale, the chief executive officer now owns 2,354,927 shares of the company’s stock, valued at $164,609,397.30. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Viking Therapeutics news, CEO Brian Lian sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $69.90, for a total value of $69,900.00. Following the completion of the sale, the chief executive officer now owns 2,354,927 shares of the company’s stock, valued at $164,609,397.30. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Marianna Mancini sold 18,026 shares of the firm’s stock in a transaction dated Tuesday, July 30th. The stock was sold at an average price of $57.13, for a total transaction of $1,029,825.38. Following the completion of the sale, the chief operating officer now directly owns 362,149 shares of the company’s stock, valued at approximately $20,689,572.37. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 516,671 shares of company stock valued at $33,810,813 over the last 90 days. Insiders own 4.70% of the company’s stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.